| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Human Endogenous Metabolite
Chitin does not have a defined pharmacological target. It is a structural polysaccharide that functions as a biomaterial rather than a drug substance. Chitin and its derivatives have been studied for various biological activities including immunomodulation, wound healing, and antimicrobial effects. The compound's mechanism of action is physical and biochemical, involving interactions with cell surface receptors and modulation of inflammatory responses. |
|---|---|
| ln Vitro |
In vitro, chitin is used as a biochemical reagent and biomaterial. It is utilized in cell culture studies for tissue engineering, wound healing research, and as a scaffold for cell growth. Chitin has been shown to stimulate immune responses in vitro, including activation of macrophages and cytokine production. The compound is also used in studies of fungal cell wall biology and as a substrate for chitinase enzyme assays.
|
| ln Vivo |
In vivo, chitin has been studied for its immunomodulatory and wound healing properties. It is used as a biomaterial in tissue engineering and as a component of wound dressings. The compound is biocompatible and biodegradable, making it suitable for various biomedical applications. Chitin is also used in agricultural applications as a plant growth promoter and in cosmetic formulations.
|
| Enzyme Assay |
For in vitro biochemical assays, chitin is used as a substrate for chitinase enzyme activity measurements. Standard protocols involve incubating chitin with chitinase enzyme in appropriate buffer and measuring the release of N-acetylglucosamine using colorimetric methods. The compound is also used in cell culture studies as a scaffold material for tissue engineering applications.
|
| Cell Assay |
For in vitro cell-based experiments, chitin is used as a biomaterial for cell culture and tissue engineering studies. Cells such as fibroblasts, osteoblasts, or chondrocytes are cultured on chitin scaffolds to assess cell adhesion, proliferation, and differentiation. The compound's biocompatibility is assessed using standard cell viability assays such as MTT or resazurin-based assays.
|
| Animal Protocol |
In vivo animal studies using chitin are conducted in models of wound healing, bone regeneration, and tissue engineering. Chitin scaffolds or dressings are implanted or applied to wounds in rodents, and tissue regeneration is assessed histologically and by measuring wound closure. The compound's immunomodulatory effects are studied by measuring cytokine levels and immune cell infiltration in treated tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of chitin are not characterized as a drug. As a high molecular weight polysaccharide, chitin is not significantly absorbed from the gastrointestinal tract. When used as an implantable biomaterial, it undergoes biodegradation by enzymes such as chitinases and lysozyme, releasing N-acetylglucosamine, which is metabolized through normal carbohydrate pathways.
|
| Toxicity/Toxicokinetics |
Chitin is generally considered to be biocompatible and non-toxic. It is widely used in biomedical and cosmetic applications. The compound has low toxicity and is not classified as hazardous under standard GHS criteria. However, standard laboratory safety practices should be followed when handling the compound. Chitin is for research use only and not for human therapeutic applications as a drug.
|
| Additional Infomation |
Chitin (CAS 1398-61-4) is primarily a research-grade biomaterial and biochemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are in materials science, tissue engineering, wound healing research, and as a substrate for enzyme assays. Chitin is also used in agriculture, cosmetics, and healthcare industries. No clinical trials or approved therapeutic indications exist for this compound as a drug.
|
| Molecular Formula |
(C8H13NO5)N
|
|---|---|
| Molecular Weight |
(203.19)n
|
| CAS # |
1398-61-4
|
| PubChem CID |
24139
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.37 g/cm3
|
| Boiling Point |
522.4ºC at 760 mmHg
|
| Melting Point |
>300°C (dec.)
|
| Flash Point |
269.8ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.6
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
15
|
| Complexity |
235
|
| Defined Atom Stereocenter Count |
5
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
